Semaglutide in India: The Complete 2026 Guide
The definitive guide to semaglutide in India — eligibility, 18+ generic brands, prices from ₹1,290/month, side effects, dosing schedules, and how to start treatment. Updated April 2026.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that mimics a natural gut hormone. It slows gastric emptying, reduces appetite, and helps regulate blood sugar. Originally developed by Novo Nordisk as Ozempic (diabetes) and Wegovy (weight management). Available in three forms: weekly injection, daily oral tablet (Rybelsus), and now 40+ generic versions in India since the patent expired March 20, 2026.
Who Is Eligible for Semaglutide in India?
South Asian BMI cutoffs apply (lower than Western): Normal 18.5-22.9, Overweight 23-24.9, Obese I 25-29.9, Obese II 30+. Eligible if BMI 27.5+ with a comorbidity (diabetes, hypertension, PCOS, fatty liver, sleep apnea) or BMI 30+ without. For Type 2 diabetes: HbA1c above 7% despite metformin.
Who Should NOT Take Semaglutide
Absolute contraindications: personal/family history of medullary thyroid cancer (MTC), MEN2 syndrome, pregnancy, Type 1 diabetes, known hypersensitivity. Relative: pancreatitis history, severe gastroparesis, severe kidney disease (eGFR below 15), eating disorders, breastfeeding.
All Generic Semaglutide Brands in India (April 2026)
- Natco Semanat/Semafull — Vial — ₹1,290-1,750/month
- Eris Sundae — Vial — ₹1,290-4,500/month
- Sun Pharma Sematrinity — Pen — ₹750-1,300/month (diabetes)
- Sun Pharma Noveltreat — Pen — ₹900-2,000/month (weight)
- Glenmark GLIPIQ — Vial — ₹1,300/month
- Alkem Semasize/Obesema — Pen — ₹1,800/month
- Zydus Semaglyn/Mashema — Reusable Pen — ₹2,200/month
- Dr. Reddy's Obeda — Pen — ₹4,200/month (Phase 3 proven)
- Novo Ozempic — Pen — ₹8,800-11,175/month (innovator)
- Novo Wegovy — Pen — ₹10,850-16,400/month (innovator)
- Novo Rybelsus — Oral Tablet — ₹2,658-4,500/month
Side Effects — What the Trials Show
Common (STEP 1 trial data): Nausea 44%, Diarrhea 30%, Vomiting 24%, Constipation 24%, Abdominal pain 20%, Headache 14%, Fatigue 11%. Most resolve within 2-4 weeks at each dose level. Slow dose escalation over 16 weeks minimizes severity.
The Clinical Evidence
- STEP 1 (NEJM 2021): 14.9% mean weight loss at 68 weeks
- SELECT (NEJM 2023): 20% reduction in major cardiovascular events (17,604 patients)
- STEP 10 (JAMA 2024): 71% of prediabetics returned to normal glucose
- SUSTAIN-6 (NEJM 2016): 26% MACE reduction in diabetes
- ICMR-INDIAB: 101.3M Indians with diabetes, 254M with obesity
Dose Escalation Schedule
Weight management: 0.25mg (weeks 1-4) → 0.5mg (5-8) → 1.0mg (9-12) → 1.7mg (13-16) → 2.4mg (17+). Diabetes: 0.25mg → 0.5mg → 1.0mg (maintenance) → 2.0mg (optional). Never skip ahead — slow escalation prevents severe side effects.
Semaglutide vs Tirzepatide (Mounjaro)
Semaglutide targets GLP-1 only. Tirzepatide (Mounjaro) targets both GLP-1 and GIP (dual agonist). Tirzepatide shows slightly higher weight loss (up to 22% vs 15.3%) but costs ₹9,200/month with no generics available. Semaglutide is 80-95% cheaper as generic, has cardiovascular outcome data (SELECT trial), and is available from 40+ Indian manufacturers.
Weight Regain After Stopping
The STEP 1 extension study showed approximately 67% of lost weight was regained within 1 year of stopping semaglutide. Most doctors now recommend long-term or indefinite use for sustained results, combined with lifestyle modifications.
Government Regulations
Semaglutide is a Schedule H drug in India — prescription required. The DCGI issued an advisory in March 2026 after inspecting 49 businesses for unauthorized sales. No surrogate advertising allowed. Buy only from licensed pharmacies with a valid prescription.
Check Your GLP-1 Eligibility — Free | Compare All Brands | Read Our Guides